Unraveling the tumor immune microenvironment in Neuroblastoma to discover novel immunotherapeutic targets in pediatric oncology
Children with high-stage neuroblastoma disease often show a poor survival rate (~50%). For this reason new therapeutic strategies are needed, especially for this high-stage group. Recently, the interest in developing immunotherapy for neuroblastom increased significantly, especially after the implementation of anti-GD2 antibody Dinutuximab into the standard care, which already showed promising results. Nevertheless, children with high-stage neuroblastoma show still a poor 5-year survival. Therefore, discovering new immunotherapeutic targets in neuroblastoma is extremely important. During this project we aim to unravel the tumor microenvironment in Neuroblastoma by performing single cell sequencing and CyTOF to discover potential immunotherapetic targets.
Contact
Francisca Bergsma